UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 15, 2022
InMed Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Its Charter)
British Columbia | | 001-39685 | | 98-1428279 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
Suite 310 – 815 W. Hastings Street Vancouver, B.C.
Canada | | V6C 1B4 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code): (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Shares, no par value | | INM | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07: Submission of Matters to a Vote of Security Holders.
On December 15, 2022, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:
Proposal No. 1—Election of Directors
The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2023 Annual General Meeting of Shareholders:
| Nominee | | Votes For | | | % Votes For | | | Votes Withheld | | | % Votes Withheld | | | Broker
Non-Votes | |
| Eric A. Adams | | | 159,223 | | | | 94.90 | % | | | 8,559 | | | | 5.10 | % | | | 179,813 | |
| Andrew Hull | | | 158,282 | | | | 94.34 | % | | | 9,500 | | | | 5.66 | % | | | 179,813 | |
| Janet Grove | | | 162,246 | | | | 96.70 | % | | | 5,536 | | | | 3.30 | % | | | 179,813 | |
| Bryan Baldasare | | | 160,764 | | | | 95.82 | % | | | 7,018 | | | | 4.18 | % | | | 179,813 | |
| Nicole Lemerond | | | 162,174 | | | | 96.66 | % | | | 5,608 | | | | 3.34 | % | | | 179,813 | |
Proposal No. 2—Appointment of Independent Registered Public Accounting Firm
The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2023 Annual General Meeting of Shareholders or until a successor is named.
| Votes For | | | % Votes For | | | Vote Against | | | % Votes Against | | | Abstain | | | Broker
Non-Votes | |
| | 339,548 | | | | 97,68% | | | | 0 | | | | 0% | | | | 8,047 | | | | 0 | |
Item 7.01 Regulation FD Disclosure.
On December 15, 2022, the Corporation issued a press release announcing the voting results of the meeting. A copy of the press release is furnished hereto as Exhibit 99.1.
The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 16, 2022
| | INMED PHARMACEUTICALS INC. |
| | |
| | By: | /s/ Eric A. Adams |
| | Name: | Eric A. Adams |
| | Title: | Chief Executive Officer |
2
